XML 42 R30.htm IDEA: XBRL DOCUMENT v3.4.0.3
Segment Information (Tables)
 9 Months Ended 12 Months Ended
Jan. 31, 2016
Apr. 30, 2015
Segment Reporting [Abstract]    
Schedule of Segment Reporting Information, by Segment [Table Text Block]
The following tables summarize, for the periods indicated, operating results by reportable segment (table in thousands):
 
 
Three Months Ended January 31, 2016
 
Personalized
Oncology
Solutions
(POS)
 
Translational
Oncology
Solutions
(TOS)
 
Unallocated
Corporate
Overhead
 
Consolidated
Net revenue
 
$
416
 
 
$
2,136
 
 
$
—
 
 
$
2,552
 
Direct cost of services
 
 
(479
) 
 
 
(1,624
) 
 
 
—
 
 
 
(2,103
) 
Sales and marketing costs
 
 
(183
) 
 
 
(569
) 
 
 
—
 
 
 
(752
) 
Other operating expenses
 
 
—
 
 
 
(950
) 
 
 
(553
) 
 
 
(1,503
) 
Stock-based compensation expense(1)
 
 
—
 
 
 
—
 
 
 
(567
) 
 
 
(567
) 
Segment profit (loss)
 
$
(246
) 
 
$
(1,007
) 
 
$
(1,120
) 
 
$
(2,373
) 
 
 
 
Three Months Ended January 31, 2015
 
Personalized
Oncology
Solutions
(POS)
 
Translational
Oncology
Solutions
(TOS)
 
Unallocated
Corporate
Overhead
 
Consolidated
Net revenue
 
$
453
 
 
$
1,376
 
 
$
—
 
 
$
1,829
 
Direct cost of services
 
 
(672
) 
 
 
(1,300
) 
 
 
—
 
 
 
(1,972
) 
Sales and marketing costs
 
 
(366
) 
 
 
(613
) 
 
 
—
 
 
 
(979
) 
Other operating expenses
 
 
—
 
 
 
(1,028
) 
 
 
(612
) 
 
 
(1,640
) 
Stock-based compensation expense(1)
 
 
—
 
 
 
—
 
 
 
(657
) 
 
 
(657
) 
Segment profit (loss)
 
$
(585
) 
 
$
(1,565
) 
 
$
(1,269
) 
 
$
(3,419
) 
 
 
 
Nine Months Ended January 31, 2016
 
Personalized
Oncology
Solutions
(POS)
 
Translational
Oncology
Solutions
(TOS)
 
Unallocated
Corporate
Overhead
 
Consolidated
Net revenue
 
$
1,387
 
 
$
6,958
 
 
$
—
 
 
$
8,345
 
Direct cost of services
 
 
(1,634
) 
 
 
(4,654
) 
 
 
—
 
 
 
(6,288
) 
Sales and marketing costs
 
 
(716
) 
 
 
(1,800
) 
 
 
—
 
 
 
(2,516
) 
Other operating expenses
 
 
—
 
 
 
(2,755
) 
 
 
(2,463
) 
 
 
(5,218
) 
Stock-based compensation expense(1)
 
 
—
 
 
 
—
 
 
 
(2,090
) 
 
 
(2,090
) 
Segment profit (loss)
 
$
(963
) 
 
$
(2,251
) 
 
$
(4,553
) 
 
$
(7,767
) 
 
 
Nine Months Ended January 31, 2015
 
Personalized
Oncology
Solutions
(POS)
 
Translational
Oncology
Solutions
(TOS)
 
Unallocated
Corporate
Overhead
 
Consolidated
Net revenue
 
$
1,245
 
 
$
4,377
 
 
$
—
 
 
$
5,622
 
Direct cost of services
 
 
(2,171
) 
 
 
(3,205
) 
 
 
—
 
 
 
(5,376
) 
Sales and marketing costs
 
 
(1,243
) 
 
 
(1,650
) 
 
 
—
 
 
 
(2,893
) 
Other operating expenses
 
 
—
 
 
 
(3,490
) 
 
 
(2,413
) 
 
 
(5,903
) 
Stock-based compensation expense(1)
 
 
—
 
 
 
—
 
 
 
(2,284
) 
 
 
(2,284
) 
Segment profit (loss)
 
$
(2,169
) 
 
$
(3,968
) 
 
$
(4,697
) 
 
$
(10,834
) 
 
(1)
 Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.
The following tables summarize, for the periods indicated, operating results by business segment (in thousands):
 
 
Year Ended April 30, 2015
 
Personalized
Oncology
Solutions
(POS)
 
Translational
Oncology
Solutions
(TOS)
 
Unallocated
Corporate
Overhead
 
Consolidated
Net revenue
 
$
1,663
 
 
$
7,200
 
 
$
—
 
 
$
8,863
 
Direct cost of services
 
 
(2,711
) 
 
 
(4,877
) 
 
 
—
 
 
 
(7,588
) 
Sales and marketing costs
 
 
(1,514
) 
 
 
(2,208
) 
 
 
—
 
 
 
(3,722
) 
Other operating expenses
 
 
—
 
 
 
(4,493
) 
 
 
(3,136
) 
 
 
(7,729
) 
Stock compensation expense(1)
 
 
—
 
 
 
—
 
 
 
(3,162
) 
 
 
(3,162
) 
Segment profit (loss)
 
$
(2,562
) 
 
$
(4,378
) 
 
$
(6,298
) 
 
$
(13,238
) 
 
 
 
Year Ended April 30, 2014
 
Personalized
Oncology
Solutions
(POS)
 
Translational
Oncology
Solutions
(TOS)
 
Unallocated
Corporate
Overhead
 
Consolidated
Net revenue
 
$
2,264
 
 
$
9,286
 
 
$
—
 
 
$
11,550
 
Direct cost of services
 
 
(2,667
) 
 
 
(3,496
) 
 
 
—
 
 
 
(6,163
) 
Sales and marketing costs
 
 
(1,723
) 
 
 
(1,080
) 
 
 
—
 
 
 
(2,803
) 
Other operating expenses
 
 
—
 
 
 
(2,209
) 
 
 
(3,828
) 
 
 
(6,037
) 
Stock compensation expense(1)
 
 
—
 
 
 
—
 
 
 
(2,807
) 
 
 
(2,807
) 
Segment loss
 
$
(2,126
) 
 
$
2,501
 
 
$
(6,635
) 
 
$
(6,260
) 
 
(1)
Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.